From: Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010
Malignancy | Type of EBV latency | Prevalence of EBV in cases (%) | Comment |
---|---|---|---|
Nasopharyngeal carcinoma (ICD10:C11) | Type II | Â | Estimates based on 2 previous studies on global burden of infection-associated cancer [1, 2]. |
 • High/intermediate incidence region |  | 100% | |
 • Low incidence region |  | 80% | |
High/intermediate regions: East Asia, South Asia, South East Asia & North Africa & Middle East [53]. All other regions were regarded as low incidence. | |||
Gastric carcinoma (ICD10:C16) | Type II | Â | Estimate based on 2 large meta-analysis studies with a cumulative total of 25,690 cases [22, 23]. |
 • Males |  | 11% | |
 • Females |  | 6% | |
Hodgkin’s disease (ICD10:C81) | Type II |  | Estimates based on 7 studies with cumulative total of 3357 cases [17, 24–29]. |
 • Children <14yrs |  | 62% | |
 • Adults 15-54yrs |  | 30% | |
 • Adults >55yrs |  | 55% | |
Burkitt’s Lymphoma (ICD10:C83.5) | Type I |  | Estimates based on 2 previous studies on global burden of infection-associated cancer [1, 2].Endemic region: Sub-Saharan Africa. |
 • Endemic |  |  | |
 90.5% of all NHL are BL in 0-14 age group [1]. |  | 95% | |
 • Intermediate |  |  | Intermediate regions: N. Africa & Middle east, Latin America. |
 33.3% of all NHL are BL in 0-14 age group [1]. |  | 50% | |
 • Non-endemic |  |  | Non-endemic: All other regions. |
 15.2% of all NHL are BL in 0-14 age group [1]. |  | 20% | BL is 3-4x more common in males [41–43, 45]. In this study we have used male:female ratio of 3:1. |
 In adults (age group 15-80+), irrespective of region, BL is estimated to constitute 2% of all NHL [39]. |  |  | |
Post-transplant lymphoproliferative disease (ICD10:D47.Z1) | Type III | Â | 80% of all PTLD were estimated to be due to EBV [30, 31]. It was assumed the risk of developing PTLD and dying from it was the same for both sexes. |
 • 1.5% of transplant recipients were estimated to developed PTLD and 50% of these died with first year of post-transplant [30, 48, 49]. |  | 80% |